At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial
In Brief
A Phase 2 clinical trial evaluating Palmidrol, Placebo Administration, and 1 other intervention for Chemotherapy-Induced Peripheral Neuropathy and 2 related conditions. Active but no longer recruiting, targeting 88 participants across 10 sites.
Detailed Summary
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.
Study Details
Timeline
Interventions
Given PEA PO
Given PO
Ancillary studies